Curated News
By: NewsRamp Editorial Staff
October 01, 2026
Lantern Pharma Closes $4M Registered Direct Offering
TLDR
- Lantern Pharma raised $4 million via a registered direct offering, potentially doubling proceeds to $8 million if warrants are fully exercised.
- Lantern Pharma closed a registered direct offering of 3,669,725 shares at $1.09 per share, with concurrent unregistered warrants for up to 3,669,725 shares.
- Lantern Pharma's AI-driven oncology research aims to bring precise, life-saving therapies to patients, making tomorrow better through innovation.
- Lantern Pharma uses its RADR AI platform to transform oncology drug development, integrating genomic data to identify patients most likely to benefit.
Impact - Why it Matters
This financing provides Lantern Pharma with additional capital to advance its AI-driven oncology pipeline, including LP-184, LP-300, and LP-284, and to support its subsidiaries Starlight Therapeutics and Open-Medicine AI. As a clinical-stage company, access to funding is critical for progressing biomarker-driven clinical trials and potentially bringing new precision cancer therapies to patients. The offering, though modest, signals continued investor interest in AI-native drug development and could enable Lantern to achieve key milestones. For investors, the dilution from the new shares and warrants is a consideration, but the funds strengthen the balance sheet and support the company’s mission to transform oncology drug development. This news matters because it highlights the ongoing convergence of artificial intelligence and biopharma, a trend that could lead to faster, more effective cancer treatments.
Summary
Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company leveraging artificial intelligence and genomic data for precision oncology, has closed a registered direct offering of 3,669,725 shares of common stock (or pre-funded warrants) at $1.09 per share. The offering raised approximately $4 million in gross proceeds before fees and expenses. In a concurrent private placement, Lantern issued unregistered warrants to purchase up to 3,669,725 shares at an exercise price of $1.09 per share, which could provide an additional $4 million if fully exercised for cash. Rodman & Renshaw LLC served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
Lantern Pharma is advancing its proprietary RADR artificial intelligence and machine-learning platform, which integrates large-scale genomic and biological data to transform the cost, pace, and precision of oncology drug development. The platform is designed to identify patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. For the latest updates, investors can visit the company’s newsroom at https://nnw.fm/LTRN.
The announcement was distributed through NetworkNewsWire (“NNW”), a specialized communications platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. To view the full press release, visit https://nnw.fm/a9u8A.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Closes $4M Registered Direct Offering
